|
|
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of products that address unmet medical needs in the acute care environment. CUBICIN (daptomycin for injection), the company’s antibiotic for the treatment of complicated skin and skin structure infections caused by susceptible strains of certain microorganisms, has been patented to provide protection in the U.S. through September 24, 2019.
Basic corporate social responsibility ratingsData sources for this companyRatings history Subcategory CSR ratings
| | Governance | Community |
|---|
| Board | Leadership Ethics | Transparency & Reporting | Community Dev & Philanthropy | Product | Human Rights & Supply Chain |
|---|
| Cubist Pharmaceuticals, Inc. | | | | | | |
| Pharmaceutical & Medicine Manufacturing | | | | | | |
| CSRHub average | 52 | 52 | 48 | 47 | 45 | 51 |
| USA | | | | | | |
| | Employees | Environment |
|---|
| Compensation & Benefits | Diversity & Labor Rights | Training, Health & Safety | Energy & Climate Change | Policy & Reporting | Resource Management |
|---|
| Cubist Pharmaceuticals, Inc. | | | | | | |
| Pharmaceutical & Medicine Manufacturing | | | | | | |
| CSRHub Average | 43 | 47 | 47 | 44 | 46 | 46 |
| USA | | | | | | |
FlagsName variants
|
|
